ClinicalTrials.gg
RecruitingNCT05417594CERTIS1Updated Oct 5, 2026

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

A Phase 1/2 interventional study of AZD9574 and Temozolomide (TMZ) in Advanced Solid Malignancies, sponsored by AstraZeneca. Recruiting at 32 sites in 7 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 4 months later.
Updated Oct 5, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
695
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies in Breast Neoplasms by AstraZeneca — 20 open to participants now, 50 under way, 24 of them phase 3. Breast Neoplasms · AstraZeneca.

Planned enrollment
23rd of 125
695 · median 148
Started
2022
with 9 others
Phase 1/2
12 of 198
2 open now
Primary completion
2028-02
later than 38 of 49 live
Registered
156th of 198
by date

Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 23rd largest by planned enrollment of the 125 interventional ones that give a count, is one of 10 that started in 2022, is one of 12 in phase 1/2, reaches primary completion later than 38 of the 49 other live ones, and was the 156th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

20 of the 198 studies in Breast Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Breast Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.

Read the detailed description

This is a modular phase I/IIa, multi-centre, multi-part, open-label, dose escalation, and dose expansion study.

Approximately 695 participants will be enrolled and assigned to study treatments.

This study consists of individual modules each evaluating safety and tolerability.

  • Core protocol which contains information applicable to all modules.
  • Module 1 (AZD9574 monotherapy):

This module will include 235 participants:

  • Part A (dose-escalation cohorts) will include participants with advanced/relapsed ovarian, breast, pancreatic or prostate cancer that are deemed suitable for a Poly ADP-Ribose Polymerase (PARPi) by the Investigator.
  • Part B (dose-expansion cohorts):

This module will include up to 3 expansion cohorts with 30 participants in each:

  • Cohort B1 will include participants with advanced/relapsed Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer participants with breast cancer gene (BRCA) mutated (BRCA1m, and BRCA2m), partner and localiser of the BRCA2 gene (PALB2) mutation (PALB2m), RAD51Cm or RAD51Dm, without evidence of untreated brain metastasis at baseline Magnetic Resonance Imaging (MRI) scan.
  • Cohort B2 will include participants with advanced/relapsed HER2-negative breast cancer participants with BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, who have either untreated or treated brain metastases that are not requiring immediate local therapy.

    • Up to of 20 participants may be required to get 12 evaluable participants in each cohort for food effect and Acid Reducing Agent (ARA) investigations.

      • Module 2 (AZD9574 in combination with temozolomide (TMZ): This module will include 75 participants for up to 12 cycles.
    • Part A (dose-escalation cohorts) will include participants with Isocitrate Dehydrogenase (IDH)-mutant glioma.

      • Module 3 (PET Sub-study: AZD9574 monotherapy [Panels 1 and 3], AZD9574 in combination with TMZ (Panel 2). This module will include 12 participants and is only applicable for Sweden.
    • Panel 1 (AZD9574 monotherapy) will include up to 8 participants with advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm.
    • Panel 2 (AZD9574 + TMZ) will include up to 2 participants with IDH-mutant recurrent glioma.
    • Panel 3 (AZD9574 monotherapy) will include up to 2 participants with breast cancer (without BM).

      • Module 4 (AZD9574 in combination with Trastuzumab deruxtecan [T-DXd])

This module will include 265 participants (including backfills):

  • Part A (dose escalation cohorts) will include participants with advanced, unresectable, or metastatic solid tumours that are HER2-positive.
  • Part B (dose expansion cohorts) will include up to 4 cohorts with participants with HER2-low/ultralow, HR positive breast cancer. Approximately 30 response evaluable participants without brain metastases or with treated and stable brain metastasis will be enrolled in each cohort and up to 10 additional participants with brain metastases (CNS cohort) may be enrolled in each cohort.

    • Module 5 (AZD9574 in combination with Datopotamab deruxtecan [Dato-DXd])

This module will include 105 participants (including backfills):

  • Part A (dose escalation cohorts) will include participants with advanced, unresectable, or metastatic solid tumours in different types of cancers.
  • Part B (dose expansion cohorts) may be added in the future amendment.
03

Conditions studied

  • Advanced Solid Malignancies

Keywords

  • Poly ADP-ribose Polymerase inhibitor (PARPi)
  • Anti-tumour
  • Breast cancer
  • Ovarian cancer
  • Fallopian tube cancer
  • Prostate cancer
  • Pancreatic cancer
  • Soft tissue disease
  • Glioma
  • Astrocytoma
  • Oliogodendroglioma
  • Solid tumours
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status (ECOG PS) with no deterioration over the previous 2 weeks.
  • Progressive cancer at the time of enrollment.
  • Adequate organ and marrow function.

Module 1:

Part A:

- Participants must have one of the following: (i) or cytologically confirmed advanced ovarian, fallopian tube or primary peritoneal cancer and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C or RAD51D (ii) Histologically or cytologically confirmed -negative carcinoma of the breast with recurrent locally advanced or disease and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.

(iii) Histologically or cytologically confirmed advanced/metastatic castration-resistant prostate cancer (CRPC) and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes:BRCA1, BRCA2, PALB2, RAD51C, or RAD51D (d) Histologically or cytologically confirmed advanced/metastatic pancreatic cancer and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.

  • Must have evaluable disease.
  • Must be suitable for treatment with a PARPi.
  • Must be capable of eating a high fat meal and adhering to fasting restrictions.

Part B:

  • Must have metastatic or recurrent locally advanced histologically or cytologically confirmed Human Epidermal growth factor Receptor 2 (HER2)-negative carcinoma of the breast and evidence of a predicted loss of function germline or tumour mutation.
  • Must have at least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter.
  • Participants who have received platinum chemotherapy for advanced breast cancer are eligible to enter the study provided there has been no evidence of disease progression during the platinum chemotherapy.
  • Participants who have received prior platinum-based chemotherapy as /adjuvant treatment are eligible provided at least 12 months have elapsed between the last dose of platinum-based treatment and first dose of study intervention.

Module 2:

  • Must be suitable for treatment with TMZ and have IDH1/2-mutant glioma.
  • Should have progressive disease after prior radiation therapy and one prior line of alkylating chemotherapy for their disease.
  • Recurrent disease must be evaluable by MRI.
  • Female participants of (CBP) must have a negative pregnancy test result at screening and prior to each cycle administration of AZD9574 and TMZ.
  • Adequate organ and marrow function.

Module 3:

Panel 1

  • Must consent to provide mandated blood samples and archival/fresh tumour tissue for confirmatory tests of their cancer using central laboratory.
  • Participants must have one of the following:

    1. Histologically or cytologically confirmed HER2-negative carcinoma of the breast with recurrent locally advanced or metastatic disease and evidence of a predicted loss of function germline or tumour mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D,
    2. Histologically or cytologically confirmed relapsed advanced ovarian, fallopian tube or primary peritoneal cancer and evidence of a predicted loss of function germline or tumour mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D
    3. Histologically or cytologically confirmed advanced/metastatic castration-resistant prostate cancer (CRPC) and evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C or RAD51D.
    4. Histologically or cytologically confirmed advanced/metastatic pancreatic cancer and evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.
  • Participants must have evaluable disease: at least one measurable and/or non- per 1.1
  • Must be refractory to standard therapy or for which no standard therapy exists.
  • Any 2 participants in this panel must meet the following CNS criteria:

    1. Must have previously treated and progressing or untreated confirmed by brain MRI at screening that do not need immediate local therapy.
    2. Should have stable neurological function for ≥ 14 days prior to signing the main study ICF.
    3. If receiving , the dose should be stable or decreasing for ≥ 14 days prior to signing the main study ICF.

Panel 2

  • Must be suitable for treatment with TMZ and have IDH1/2-mutant glioma.
  • Should have progressive disease after prior radiation therapy and one prior line of alkylating chemotherapy for their disease.
  • Recurrent disease must be evaluable by MRI and at least 1 tumour of > 1cm diameter detected on MRI.
  • Formalin-fixed, paraffin-embedded (FFPE) tumour sample from the primary cancer must be available for central testing
  • Adequate organ and marrow function (in the absence of transfusions or growth factor support within 14 days prior to enrolment)

Panel 3

  • Must consent to provide mandated blood samples and archival/fresh tumour tissue for confirmatory tests of their cancer using central laboratory.
  • Must have histologically or cytologically confirmed HER2-negative carcinoma of the breast with recurrent locally advanced or metastatic disease and evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C or RAD51D .
  • Must have evaluable disease: at least one measurable and/or non-measurable lesions per RECIST 1.1 .
  • Must be refractory to standard therapy or for which no standard therapy exists.

Module 4:

Part A:

  • Must have the following HER2 status:

    1. Breast cancer must be IHC 3+ or IHC 2+/ISH-positive or IHC 2+/ISH-negative or IHC 1+ as determined by local testing using current American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines for scoring HER2 + breast cancer.
    2. Gastric cancer should be IHC 3+ or IHC 2+/ISH-positive based on local tissue testing results.
    3. Participants with non-breast and non-gastric cancers must have HER2-overexpression (IHC 3+ or IHC 2+; as determined by local testing using current ASCO-CAP guidelines for gastric IHC scoring).
    4. Participants with NSCLC will also be eligible based on the presence of a HER2activating mutation.
  • Must have progressed following at least one prior systemic treatment and not more than 2 prior lines of cytotoxic therapy for metastatic or advanced disease and have no satisfactory alternative treatment option.
  • Should have unresectable, or metastatic disease based on most recent imaging. The following tumour types are eligible for this study: Breast cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Gastric Cancer, and Other tumour types ( unresectable or metastatic biliary tract cancer, cervical cancer, endometrial cancer, and pancreatic adenocarcinoma).
  • Adequate organ and marrow function (in the absence of transfusions or growth factor support) within 14 days prior to the first dose of study intervention.
  • (LVEF) ≥ 50% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before start of treatment.
  • Must have at least one lesion not previously irradiated (or with evidence of disease progression following radiation).
  • Non-sterilised male participants who are sexually active with a female partner of CBP must use a condom with spermicide from screening to approximately 6 months after the last dose of study intervention.
  • Male participants must refrain from fathering a child or donating sperm during the study and for approximately 6 months after the last dose of study intervention.

Part B - All participants:

  • Histologically documented unresectable or metastatic breast cancer.
  • Metastatic or recurrent locally advanced unresectable histologically or cytologically confirmed HER2-low or HER2-ultralow breast carcinoma.
  • No prior chemotherapy for locally advanced unresectable or metastatic breast cancer.

Part B - Participants with brain metastases:

  • Stable neurological function for ≥ 14 days prior to signing the main study ICF.
  • If receiving steroids, the dose should be stable or decreasing for ≥ 14 days prior to signing the main study ICF.
  • Must not have progressing or untreated (stable or progressing) brain metastases.

Part B - Participants in CNS cohort:

- Untreated brain metastases, previously treated and stable or progressing brain metastases on screening contrast brain MRI/CT scan, not needing immediate local therapy.

Module 5 :

  • Should have unresectable, or metastatic disease based on most recent imaging. The following tumour types are eligible for this study: TNBC, Endometrial cancer, Ovarian Cancer and CRPC.
  • Must have progressed following at least one prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment option.
  • Must have at least one lesion, not previously irradiated that can be accurately measured at baseline as ≥ 10 mm in the longest diameter.
  • Non-sterilised male participants who are sexually active with a female partner of CBP must use a condom with spermicide from screening to approximately 4 months after the last dose of study.
  • Male participants must refrain from fathering a child or donating sperm during the study and for approximately 4 months after the last dose of study intervention.
  • Adequate organ and marrow function (in the absence of transfusions or growth factor support) within 14 days prior to the first dose of study intervention.

Modules 1, 2 and 3:

  • Female participants of CBP:

    1. Must have a negative pregnancy test result at screening and prior to each cycle of study treatment.
    2. If sexually active with a non-sterilised male partner, must use at least one highly effective method of plus a barrier method from screening to approximately 6 months after the last dose of study treatment.
  • Female participants must not breastfeed and must not donate or retrieve ova for their own use from screening to approximately 6 months after the last dose of study treatment.
  • Non-sterilised male participants who are sexually active with a female partner of CBP must use a condom with spermicide from screening to approximately 3 months after the last dose of study intervention.
  • Female partners of male participants should use at least one highly effective method of contraception from screening to approximately 3 months after the last dose of study intervention of the male participant.
  • Male participants must refrain from fathering a child or donating sperm from the start of study intervention and for approximately 3 months after the last dose of study intervention.

Modules 4 and 5:

  • Female participants of CBP:

    1. Must have a negative pregnancy test result at screening and prior to each cycle of study intervention.
    2. If sexually active with a non-sterilised male partner, must use at least one highly effective method of birth control in combination with one effective method (male condom plus spermicide) from screening until approximately 7 months after the last dose of study intervention.
  • Female participants must not breastfeed and must not donate or retrieve ova for any use from screening to approximately 7 months after the last dose of study intervention.
  • Participants must provide an existing FFPE tumour sample for retrospective, tissue-based IHC testing in a central laboratory to determine HER2 expression and other correlatives.
  • ECOG performance status of 0 or 1.
  • Participants recruited specifically for PD evaluation must have at least 1 tumour suitable for paired and be willing to consent to pre-treatment and on-treatment biopsies.

Exclusion criteria

Exclusion Criteria:

  • Major surgery within 4 weeks of the first dose of study intervention.
  • Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study intervention.
  • With the exception of alopecia, any unresolved toxicities from prior therapy greater than (CTCAE) Grade 1 at the time of starting study intervention.
  • Any known history of persisting severe pancytopenia due to any cause.
  • Spinal cord compression unless asymptomatic, treated and stable and not requiring continuous at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study intervention.
  • History of uncontrolled seizures or with need for concurrent administration of more than 2 antiepileptic drugs, or history of epileptic disorder or any seizure history unrelated to tumour.
  • History of severe brain injury or stroke.
  • Any evidence of severe or uncontrolled systemic diseases including active bleeding diatheses, active infection including , and (HIV).
  • Uncontrolled intercurrent illness within the last 12 months.
  • Any known predisposition to bleeding.
  • Patients with myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML.
  • nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD9574.
  • Known allergy or to product(s) or any of the of the investigational product(s).
  • Known to gadolinium-enhanced Magnetic Resonance Imaging (MRI) or, if applicable, not able to be maintained on a stable or decreasing dose of corticosteroid regimen (no increase for 7 days) prior to the baseline MRI.
  • Any concurrent anti-cancer therapy or concurrent use of prohibited medications.

Module 1:

Part A:

  • Have received > one in any setting with a PARPi-based regimen.
  • Participants with an >1.5 unless the patient is receiving non-vitamin K antagonist oral anticoagulants.
  • Participants with (LMD) unless the LMD is of low volume or is previously treated and the participant is asymptomatic or minimal symptoms.
  • Participants with insulin-dependent diabetes.
  • Currently on ARA treatment.

Part B:

  • Participants with an International Normalised Ratio (INR) >1.5 unless the patient is receiving non-vitamin K antagonist oral anticoagulants.
  • Participants with LMD are excluded unless the LMD is of low volume or is previously irradiated and the participant is asymptomatic from the LMD.

Module 2:

  • Received a PARPi previously.
  • Known hypersensitivity to TMZ or dacarbazine or known history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9574.
  • Have received > 1 prior line of alkylating chemotherapy regimen. Participants who have received procarbazine, lomustine (CCNU), vincristine (PCV) as a prior line of treatment are not allowed.
  • Previously experienced Grade 4 haematological toxicities or Grade 3 neutropenia associated with infections, or Grade 3 thrombocytopenia with bleeding during prior alkylating chemotherapy.
  • Received bevacizumab within the last 6 months.
  • Not requiring continuous corticosteroids at a dose of >10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study intervention.

Module 3:

All Panels

  • Positive Allen's test
  • > 30.0 kg/m2 or body weight > 100.0 kg
  • Suffer from claustrophobia.
  • Implanted metal devices or implants containing metal.
  • An INR >1.5
  • Taking acid-reducing agents.

Panel 1

  • Received > 1 prior line of therapy in any setting with a PARPi-based regimen
  • Participants with LMD

Panel 2

  • Received a PARPi previously.
  • Known hypersensitivity to TMZ.
  • Received > 1 prior line of alkylating chemotherapy regimen.
  • Previously experienced Grade 4 haematological toxicities or Grade 3 neutropenia associated with infections, or Grade 3 thrombocytopenia with clinically significant bleeding during prior alkylating chemotherapy.
  • Received bevacizumab within the last 6 months.

Panel 3

  • Received > one prior line of therapy in any setting with a PARPi-based regimen.
  • Participants with LMD.

Module 4:

All participants:

  • Current or prior use of medication within 14 days before the first dose of T-DXd and within 4 weeks for continuous corticosteroids at a dose of approximately > 10 mg prednisone/day or equivalent.
  • Should not have received more than 2 prior lines of systemic cytotoxic therapy.
  • Prior treatment with directed TOPO1i ADCs and prior AZD9574 is not permitted.
  • Must not enter the study if they received chloroquine/hydroxychloroquine \< 14 days prior to the first dose.
  • Presence of unresolved toxicities from previous anti-cancer therapy, defined as toxicities not yet resolved to Grade ≤ 1 or baseline.
  • Known history of prior transfusion(s) or febrile neutropenia in the advanced disease treatment setting.
  • Medical history of myocardial infarction. Participants with troponin levels above at screening and without any myocardial related symptoms.
  • History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis.
  • Additional lung-related exclusion criteria: (a) Lung-specific intercurrent clinically significant illnesses (b) Any , connective tissue or inflammatory disorders (c) Prior pneumonectomy.
  • Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy.
  • Known hypersensitivity to T-DXd, any of the excipients or other mAbs.
  • History of another primary .
  • An uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
  • Active primary immunodeficiency, known uncontrolled active HIV infection or active hepatitis B or hepatitis C infection.

Part A (dose escalation):

- Participants with are excluded unless asymptomatic, treated, and participant is clinically stable and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to study intervention.

Part B (dose expansion):

- Prior systemic cytotoxic-containing treatment in the /locally advanced unresectable setting.

Part B (dose expansion) - Participants with Brain Metastases:

  • Known and symptomatic leptomeningeal disease.
  • Spinal cord compression.

Module 5:

  • Current or prior use of immunosuppressive medication within 14 days before the first dose of Dato-DXd and within 4 weeks for continuous corticosteroids at a dose of approximately > 10 mg prednisone/day or equivalent.
  • Corticosteroid mouthwash formulations are permitted to prevent and manage certain AEs.
  • Prior anti-cancer treatments:

    1. Should not have received more than 2 prior lines of systemic cytotoxic therapy
    2. Prior treatment with PARPi is permitted
    3. Prior TOPO1 inhibitor therapy is NOT permitted
    4. Prior treatment with TROP2-directed ADCs is NOT permitted.
    5. Prior radiation therapy requires the .
  • Must not enter the study if they received chloroquine / hydroxychloroquine \< 14 days prior to the first dose.
  • History of another primary malignancy.
  • History of non-infectious ILD/pneumonitis including radiation pneumonitis that required steroids, has current or suspected ILD/pneumonitis.
  • Clinically severe pulmonary function compromise.
  • Clinically significant corneal disease.
  • History of severe hypersensitivity reactions to Dato-DXd, any of the excipients or to other mabs.
  • Participant is pregnant or breastfeeding or planning to become pregnant.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
695 participants (estimated)

Study arms

  • Experimental
    Module 1 Part A: Dose escalation

    Participants with advanced/relapsed ovarian, breast, pancreatic, or prostate cancer who are deemed suitable for a PARPi will receive AZD9574 monotherapy at escalating cohorts.

    Drug: AZD9574

  • Experimental
    Module 1 Part B: Dose expansion

    Participants with breast cancer who are PARPi naive at doses determined in dose-escalation.

    Drug: AZD9574

  • Experimental
    Module 2 Part A: Dose escalation

    Participants with IDH 1/2-mutant glioma who are PARPi naive will receive AZD9574 and TMZ at escalating cohorts.

    Drug: AZD9574 · Drug: Temozolomide (TMZ)

  • Experimental
    Module 3 Panel 1: AZD9574 monotherapy (Sweden only)

    Participants with advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm.

    Drug: AZD9574 · Drug: [11C]AZ1419 3391

  • Experimental
    Module 3 Panel 2: AZD9574 + TMZ (Sweden only)

    Participants with IDH 1/2-mutant glioma who are PARPi naive will receive AZD9574 and TMZ at escalating cohorts.

    Drug: AZD9574 · Drug: Temozolomide (TMZ) · Drug: [11C]AZ1419 3391

  • Experimental
    Module 3 Panel 3: AZD9574 monotherapy (Sweden only)

    Participants with breast cancer (without BM).

    Drug: AZD9574 · Drug: [11C]AZ1419 3391

  • Experimental
    Module 4 Part A: Dose escalation (AZD9574 + T-DXd)

    Participants with advanced, unresectable, or metastatic solid tumours that are HER2-positive will receive a combination of AZD9574 and T-DXd at at escalating cohorts.

    Drug: AZD9574 · Drug: Trastuzumab Deruxtecan (T-DXd)

  • Experimental
    Module 4 Part B : Dose expansion (AZD9574 + T-DXd)

    Participants with HER2-low/ultralow, HR positive breast cancer will receive a combination of different doses of AZD9574 and T-DXd at expanding cohorts.

    Drug: AZD9574 · Drug: Trastuzumab Deruxtecan (T-DXd)

  • Experimental
    Module 5 Part A : Dose escalation (AZD9574 + Dato-DXd)

    Participants with advanced, unresectable, or metastatic solid tumours in different types of cancers will receive a combination of AZD9574 and Dato-DXd at escalating cohorts.

    Drug: AZD9574 · Drug: Datopotamab Deruxtecan (Dato-DXd)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs), and Serious Adverse Events (SAEs)

    The safety and tolerability of AZD9574 as monotherapy and in combination with anti-cancer agents and TMZ in participants with advanced malignancies will be assessed.

    Time frame: From first dose to post-treatment follow-up (approximately three years)

  2. Changes from baseline in laboratory findings, electrocardiograms (ECGs), and vital signs

    The safety and tolerability of AZD9574 as monotherapy and in combination with anti-cancer agents and TMZ in participants with advanced malignancies will be assessed.

    Time frame: From last assessment prior to first dose to post-treatment follow up visit (approximately three years)

  3. Change from baseline Eastern Cooperative Oncology Group performance status (ECOG PS)

    The performance status of ECOG will be assessed based on an ECOG grade of 0 to 4 where '0' is a high grade while '4' is a low grade. An ECOG grade of '0' means that the participant is fully active, able to carry on all pre-disease performance without restriction. An ECOG grade of '4' means that the participant is completely disabled, cannot carry on any self-care, and is totally confined to a bed or chair.

    Time frame: From last assessment prior to first dose to post-treatment follow up visit (approximately three years)

  4. Incidence of Dose Limiting Toxicities (DLTs)

    The safety and tolerability of AZD9574 as monotherapy and in combination with anti-cancer agents in participants with advanced malignancies will be assessed at each dose level.

    Time frame: Cycle 0 and Cycle 1 (Day 1 to Day 35)

Secondary outcomes

  1. Area Under the Curve (AUC)

    The AUC of AZD9574 following a single dose and at steady state after multiple dosing, when given orally as monotherapy and in combination with anti-cancer agents will be evaluated.

    Time frame: Cycle 0, Cycle 1 Day 1, Cycle 1 Day 16 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  2. Maximum plasma concentration (Cmax)

    The Cmax of AZD9574 following a single dose and at steady state after multiple dosing, when given orally as monotherapy and in combination with anti-cancer agents will be evaluated.

    Time frame: Cycle 0, Cycle 1 Day 1, Cycle 1 Day 16 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  3. Time taken to reach maximum plasma concentration (tmax)

    The tmax of AZD9574 following a single dose and at steady state after multiple dosing, when given orally as monotherapy and in combination with anti-cancer agents will be evaluated.

    Time frame: Cycle 0, Cycle 1 Day 1, Cycle 1 Day 16 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  4. Minimum plasma concentration at steady state (Cmin,ss)

    The Cmin,ss of AZD9574 following a single dose and at steady state after multiple dosing, when given orally as monotherapy and in combination with anti-cancer agents will be evaluated.

    Time frame: Cycle 0, Cycle 1 Day 1, Cycle 1 Day 16 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  5. Half-life (t1/2)

    The t1/2 of AZD9574 following a single dose and at steady state after multiple dosing, when given orally as monotherapy and in combination with anti-cancer agents will be evaluated.

    Time frame: Cycle 0, Cycle 1 Day 1, Cycle 1 Day 16 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  6. Accumulation ratio

    The accumulation ratio of AZD9574 following a single dose and at steady state after multiple dosing, when given orally as monotherapy and in combination with anti-cancer agents will be evaluated.

    Time frame: Cycle 0, Cycle 1 Day 1, Cycle 1 Day 16 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  7. Dose proportionality

    The dose proportionality of AZD9574 following a single dose and at steady state after multiple dosing, when given orally as monotherapy and in combination with anti-cancer agents will be evaluated.

    Time frame: Cycle 0, Cycle 1 Day 1, Cycle 1 Day 16 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  8. Module 1: Assessment of pH2AX (phospho-histone 2AX) (Ser139) PD biomarker modulations

    The PD biomarker modulations of pH2AX (Ser139) at baseline and during treatment or pre-treatment will be assessed in tumour tissue when given orally as monotherapy.

    Time frame: Screening, Cycle 0 Day 1, Cycle 1 Day 8, and Cycle 1 day 15 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  9. Module 1: Percentage change in target lesion (TL) size

    The percentage change in TL size will be determined for participants with measurable disease at baseline and is derived at each visit.

    Time frame: From Baseline to every 8 weeks until disease progression (approximately three years)

  10. Module 1: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who have a confirmed response of Complete Response (CR) or Partial Response (PR) prior to any evidence of progression according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1) for solid tumours, RECIST v1.1 and/or Prostate Cancer Working Group 3 (PCWG3 \[bone\]) for prostate cancer, and Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) for brain metastases.

    Time frame: From Baseline to every 8 weeks until disease progression (approximately three years)

  11. Module 1: Duration of Response (DoR)

    The DoR is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression or death in the absence of disease progression according to RECIST v1.1 for solid tumours, RECIST v1.1 and/or PCWG3 for prostate cancer, and RANO-BM for brain metastases.

    Time frame: First documented response until the date of documented progression or end of study (approximately three years)

  12. Module 1: Time To Response (TTR)

    TTR is defined as the time from first dose until the first documentation of a subsequently confirmed objective response according to RECIST v1.1 for solid tumours, RECIST v1.1 and/or PCWG3 for prostate cancer, and RANO-BM for brain metastases.

    Time frame: From the first dose until the first documentation of a subsequently confirmed objective response (approximately three years)

  13. Module 1: Progression Free Survival (PFS)/radiographic Progression-Free Survival (rPFS)

    PFS and rPFS are defined as the time from start of first treatment until the date of objective disease progression or death regardless of whether the participant withdraws from study therapy or receives another anti-cancer therapy prior to progression according to RECIST v1.1 for solid tumours, RECIST v1.1 and/or PCWG3 for prostate cancer, and RANO-BM for brain metastases.

    Time frame: From the start of first treatment until the date of objective disease progression or death (approximately three years)

  14. Module 1: Cancer Antigen 125 (CA125) response evaluated according to the gynecologic cancer intergroup (GCIG) criteria (for ovarian patients only)

    CA125 response is defined as at least a 50% reduction in CA125 levels from a pre-treatment sample.

    Time frame: From Screening until disease progression or death (approximately three years)

  15. Module 1: Proportion of participants achieving a ≥ 50% decrease in PSA from baseline to the lowest post-baseline PSA result (for prostate cancer only)

    PSA50 response is defined as the proportion of participants achieving a ≥ 50% decrease in Prostate Specific Antigen (PSA) from baseline to the lowest post-baseline PSA, confirmed by a consecutive PSA at least 3 weeks later and will be based on PSA evaluable participants.

    Time frame: From screening until disease progression or death (approximately three years)

  16. Module 1: Radiological response evaluated according to RECIST v1.1 + Prostate Cancer Working Group 3 (PCWG3) response evaluation criteria (for prostate cancer only)

    In participants with prostate cancer, disease progression will be deemed to have occurred if soft tissue disease progression, bone lesion progression, or death are met.

    Time frame: Up to the End Of Trial (EOT) [approximately three years]

  17. Module 1 (Food effect): AUC

    To investigate the effect of a high-fat meal on the AUC of AZD9574 (Fasted and fed state).

    Time frame: Cycle 0 Day 1,2,3, Cycle 1 Day 1,2,8 to 15 and Cycle 2 Day 1, and Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  18. Module 1 (Food effect) : Area under the curve from 0 to t [AUC (0-t)]

    To investigate the effect of a high-fat meal on the AUC (0-t) of AZD9574 (Fasted and fed state).

    Time frame: Cycle 0 Day 1,2,3, Cycle 1 Day 1,2,8 to 15 and Cycle 2 Day 1, and Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  19. Module 1 (Food effect): Cmax

    To investigate the effect of a high-fat meal on the Cmax of AZD9574 (Fasted and fed state).

    Time frame: Cycle 0 Day 1,2,3, Cycle 1 Day 1,2,8 to 15 and Cycle 2 Day 1, and Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  20. Module 1 (Food effect): tmax

    To investigate the effect of a high-fat meal on the tmax of AZD9574 (Fasted and fed state).

    Time frame: Cycle 0 Day 1,2,3, Cycle 1 Day 1,2,8 to 15 and Cycle 2 Day 1, and Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  21. Module 1 (Food effect) : Maximum plasma concentration (Cmax) ratio (with /without a high fat meal)

    To investigate the effect of a high-fat meal on the Cmax ratio of AZD9574 (Fasted and fed state).

    Time frame: Cycle 0 Day 1,2,3, Cycle 1 Day 1,2,8 to 15 and Cycle 2 Day 1, and Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  22. Module 1 (ARA effect): AUC

    To assess the effect of rabeprazole on the AUC of AZD9574 (with and without rabeprazole).

    Time frame: Cycle 0 Day 1,3, Cycle 1 Day 1,2,8 to 15,16, Cycle 2 Day 1, Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  23. Module 1 (ARA effect): AUC (0-t)

    To assess the effect of rabeprazole on the AUC (0-t) of AZD9574 (with and without rabeprazole).

    Time frame: Cycle 0 Day 1,3, Cycle 1 Day 1,2,8 to 15,16, Cycle 2 Day 1, Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  24. Module 1 (ARA effect): Cmax

    To assess the effect of rabeprazole on the Cmax of AZD9574 (with and without rabeprazole).

    Time frame: Cycle 0 Day 1,3, Cycle 1 Day 1,2,8 to 15,16, Cycle 2 Day 1, Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  25. Module 1 (ARA effect): tmax

    To assess the effect of rabeprazole on the tmax of AZD9574 (with and without rabeprazole).

    Time frame: Cycle 0 Day 1,3, Cycle 1 Day 1,2,8 to 15,16, Cycle 2 Day 1, Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  26. Module 1 (ARA effect) : Cmax ratio (with /without rabeprazole)

    To assess the effect of rabeprazole on the Cmax ratio of AZD9574 (with and without rabeprazole).

    Time frame: Cycle 0 Day 1,3, Cycle 1 Day 1,2,8 to 15,16, Cycle 2 Day 1, Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  27. Module 2: Percentage change in TL size

    The percentage change in TL size will be determined for participants with measurable disease at baseline and is derived at each visit by the measurability of TL according to Response Assessment in Neuro-Oncology - high-grade glioma (RANO-HGG) or Response Assessment in Neuro-Oncology - low-grade glioma (RANO-LGG).

    Time frame: From Baseline to every 8 weeks until objective disease progression (approximately three years)

  28. Module 2: ORR

    The ORR is defined as the percentage of participant with high- or low-grade gliomas with at least one visit response of CR or PR according to RANO-HGG or RANO-LGG.

    Time frame: From Baseline to every 8 weeks until objective disease progression (approximately three years)

  29. Module 2: DoR

    The DoR is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression according to RANO-HGG or RANO-LGG.

    Time frame: First documented response until the date of documented progression or end of study (approximately three years)

  30. Module 2: TTR

    TTR is defined as the time from first dose until the first documentation of a subsequently confirmed objective response according to RANO-HGG or RANO-LGG.

    Time frame: First dose until the first documentation of a subsequently confirmed objective response (approximately three years)

  31. Module 2: PFS

    The PFS is defined as the time from the start of study intervention until the date of objective disease progression or death regardless of whether the participant withdraws from study intervention or receives another anti-cancer therapy prior to progression according to RANO-HGG or RANO-LGG.

    Time frame: From the start of first treatment until the date of objective disease progression or death (approximately three years)

  32. Module 3: Occupancy

    Occupancy (%) is defined as the estimated difference in radioligand binding to PARP1 from baseline to positron emission tomography (PET) examination after drug administration.

    Time frame: From Screening to Cycle 2 Day 1

  33. Module 3: AUC

    The AUC of AZD9574 following single dose and at steady state after multiple dosing, when given orally as monotherapy and in combination with TMZ will be evaluated.

    Time frame: Cycle 0 Day 1 & 5, Cycle 1 Day 5 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  34. Module 3: Cmax

    The Cmax of AZD9574 following single dose and at steady state after multiple dosing, when given orally as monotherapy and in combination with TMZ will be evaluated.

    Time frame: Cycle 0 Day 1 & 5, Cycle 1 Day 5 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  35. Module 3: tmax

    The tmax of AZD9574 following single dose and at steady state after multiple dosing, when given orally as monotherapy and in combination with TMZ will be evaluated.

    Time frame: Cycle 0 Day 1 & 5, Cycle 1 Day 5 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  36. Module 3: Cmin,ss

    The Cmin,ss of AZD9574 following single dose and at steady state after multiple dosing, when given orally as monotherapy and in combination with TMZ will be evaluated.

    Time frame: Cycle 0 Day 1 & 5, Cycle 1 Day 5 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  37. Module 3: t1/2

    The t1/2 of AZD9574 following single dose and at steady state after multiple dosing, when given orally as monotherapy and in combination with TMZ will be evaluated.

    Time frame: Cycle 0 Day 1 & 5, Cycle 1 Day 5 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  38. Module 3: Accumulation ratio

    The accumulation ratio of AZD9574 following single dose and at steady state after multiple dosing, when given orally as monotherapy and in combination with TMZ will be evaluated.

    Time frame: Cycle 0 Day 1 & 5, Cycle 1 Day 5 (Cycle 0 = 7 days; Cycle 1 = 28 days)

  39. Module 3: Percentage change in target lesion (TL) size

    The percentage change in TL size will be determined for participants with measurable disease at baseline and is derived at each visit.

    Time frame: From Baseline to every 8 weeks until disease progression (approximately three years)

  40. Module 3: ORR

    ORR is defined as the percentage of participants who have a confirmed response of Complete Response (CR) or Partial Response (PR) prior to any evidence of progression according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1) for solid tumours, RECIST v1.1 and/or Prostate Cancer Working Group 3 (PCWG3 \[bone\]) for prostate cancer, and Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) for brain metastases and according to Response Assessment in Neuro-Oncology - high-grade glioma (RANO-HGG) or Response Assessment in Neuro-Oncology - low-grade glioma (RANO-LGG).

    Time frame: From Baseline to every 8 weeks until disease progression (approximately three years)

  41. Module 3: DoR

    The DoR is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression or death in the absence of disease progression according to RECIST v1.1 for solid tumours, RECIST v1.1 and/or PCWG3 for prostate cancer, RANO-BM for brain metastases and RANO-HGG or RANO-LGG.

    Time frame: First documented response until the date of documented progression or end of study (approximately three years)

  42. Module 3: TTR

    TTR is defined as the time from first dose until the first documentation of a subsequently confirmed objective response according to RECIST v1.1 for solid tumours, RECIST v1.1 and/or PCWG3 for prostate cancer, RANO-BM for brain metastases and RANO-HGG or RANO-LGG.

    Time frame: From the first dose until the first documentation of a subsequently confirmed objective response (approximately three years)

  43. Module 3: Cancer Antigen 125 (CA125) response evaluated according to the GCIG criteria (for ovarian patients only)

    CA125 response is defined as at least a 50% reduction in CA125 levels from a pre-treatment sample.

    Time frame: From Screening until disease progression or death (approximately three years)

  44. Module 3: Proportion of participants achieving a ≥ 50% decrease in PSA from baseline to the lowest post-baseline PSA result (for prostate cancer only)

    PSA50 response is defined as the proportion of participants achieving a ≥ 50% decrease in Prostate Specific Antigen (PSA) from baseline to the lowest post-baseline PSA, confirmed by a consecutive PSA at least 3 weeks later and will be based on PSA evaluable participants.

    Time frame: From screening until disease progression or death (approximately three years)

  45. Module 3: Progression Free Survival (PFS)/radiographic Progression-Free Survival (rPFS)

    PFS and rPFS are defined as the time from start of first treatment until the date of objective disease progression or death regardless of whether the participant withdraws from study therapy or receives another anti-cancer therapy prior to progression according to RECIST v1.1 for solid tumours, RECIST v1.1 and/or PCWG3 for prostate cancer, RANO-BM for brain metastases and RANO-HGG or RANO-LGG.

    Time frame: From the start of first treatment until the date of objective disease progression or death (approximately three years)

  46. Module 3: Radiological response evaluated according to RECIST v1.1 + Prostate Cancer Working Group 3 (PCWG3) response evaluation criteria (for prostate cancer only)

    In participants with prostate cancer, disease progression will be deemed to have occurred if soft tissue disease progression, bone lesion progression, or death are met.

    Time frame: Up to the End Of Trial (EOT) [approximately three years]

  47. Module 4 : AUC

    To characterise the AUC of AZD9574, T-DXd following a single dose and at steady state after multiple dosing, when given in combination with T-DXd.

    Time frame: AZD9574 (Parts A and B): Cycle (C) 1 Day (D) X1 (first dose), X2 (last dose), C2 D1, X1 (first dose), D15 (part A only), and C3 D1 T DXd: C1 D1, X1 (pre-dose AZD9574), X2, C2 D1, C3 D1, and C4 D1, up to safety follow-up (40-days after last dose)

  48. Module 4 : Cmax

    To characterise the Cmax of AZD9574, T-DXd following a single dose and at steady state after multiple dosing, when given in combination with T-DXd.

    Time frame: AZD9574 (Parts A and B): C1 X1 (first dose), X2 (last dose), C2 D1, X1 (first dose), D15 (part A only), and C3 D1 T DXd: C1 D1, X1 (pre-dose AZD9574), X2, C2 D1, C3 D1, and C4 D1, up to safety follow-up (40-days after last dose)

  49. Module 4 : tmax

    To characterise the tmax of AZD9574, T-DXd following a single dose and at steady state after multiple dosing, when given in combination with T-DXd.

    Time frame: AZD9574 (Parts A and B): C1 X1 (first dose), X2 (last dose), C2 D1, X1 (first dose), D15 (part A only), and C3 D1 T DXd: C1 D1, X1 (pre-dose AZD9574), X2, C2 D1, C3 D1, and C4 D1, up to safety follow-up (40-days after last dose)

  50. Module 4 : Assessment of pH2AX (phospho-histone 2AX) (Ser139) PD biomarker modulations

    To characterise the PD of AZD9574 in tumour tissue, following a single dose and at steady state after multiple dosing, when given orally in combination with T-DXd.

    Time frame: Cycle 1 Day X1, Day X2 [last of AZD9574 dosing] (Cycle 1 = 28 days)

  51. Module 4 : Presence of ADAs for T-DXd

    To investigate the immunogenicity of T-DXd.

    Time frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Safety follow-up (FU) 40 [+ 7] days after last dose

  52. Module 4 : Incidence of Adverse event of special interest (AESI)

    To monitor risks associated with T-DXd (AESI) in study participants.

    Time frame: From first dose until the safety FU (40 [+ 7] days) after discontinuation

  53. Module 4 (Part A): ORR

    ORR is defined as the percentage of participants who have a confirmed response of Complete Response (CR) or Partial Response (PR) prior to any evidence of progression according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1).

    Time frame: From Baseline to every 6 weeks until disease progression (approximately three years)

  54. Module 4 (Part B): ORR

    ORR is defined as the percentage of participants who have a confirmed response of CR or PR prior to any evidence of progression according to RECIST v1.1, RECIST v1.1 and RANO-BM for participants with brain metastasis.

    Time frame: From Baseline to every 6 weeks for the first 24 weeks and then every 9 weeks until disease progression (approximately three years)

  55. Module 4 (Part A): DoR

    The DoR is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression or death in the absence of disease progression according to RECIST v1.1.

    Time frame: First documented response until the date of documented progression or end of study (approximately three years)

  56. Module 4 (Part B): DoR

    The DoR is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression or death in the absence of disease progression according to RECIST v1.1, RECIST v1.1 and RANO-BM for participants with brain metastasis.

    Time frame: First documented response until the date of documented progression or end of study (approximately three years)

  57. Module 4 (Part A): PFS

    PFS is defined as the time from start of first treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraws from study therapy or receives another anti-cancer therapy prior to progression according to RECIST v1.1.

    Time frame: From the start of first treatment until the date of objective disease progression or death (approximately three years)

  58. Module 4 (Part B): PFS

    PFS is defined as the time from start of first treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraws from study therapy or receives another anti-cancer therapy prior to progression according to RECIST v1.1, RECIST v1.1 and RANO-BM for participants with brain metastasis.

    Time frame: From the start of first treatment until the date of objective disease progression or death (approximately three years)

  59. Module 4 (Part A): TTR

    TTR is defined as the time from first dose until the first documentation of a subsequently confirmed objective response according to RECIST v1.1.

    Time frame: From the first dose until the first documentation of a subsequently confirmed objective response (approximately three years)

  60. Module 4 (Part B): TTR

    TTR is defined as the time from first dose until the first documentation of a subsequently confirmed objective response according to RECIST v1.1, RECIST v1.1 and RANO-BM for participants with brain metastasis.

    Time frame: From the first dose until the first documentation of a subsequently confirmed objective response (approximately three years)

  61. Module 4 (Part B only): Progression-free survival at 6 months (PFS6)

    The PFS is defined as the time from the start of study intervention until the date of objective disease progression or death regardless of whether the participant withdraws from study intervention or receives another anti-cancer therapy prior to progression according to RECIST v1.1, RECIST v1.1 and RANO-BM for participants with brain metastasis.

    Time frame: At 6 months after start of first treatment

  62. Module 4 (Part B): Number of participants experiencing each level of symptomatic AEs as measured by the Patient-Reported Outcomes Version of the common terminology criteria for adverse events (PRO-CTCAE)

    The PRO-CTCAE is an item library of symptoms experienced by participants while undergoing treatment of their cancer. It assess the presence/absence, severity, frequency, and interference of treatment-related symptoms from the participant's perspective.

    Time frame: From the first dose until the end of 12 months or EOT, whichever comes first (approximately three years)

  63. Module 4 (Part B): Number of participants reporting overall side effect bother on the patient's global impression of treatment tolerability (PGI-TT) while receiving treatment

    The PGI-TT is a single item assessment of the participant's overall level of bother due to treatment-related side effects of cancer treatment over a 1-week period. Participants will be asked to choose the response that best describes the severity of their overall cancer symptoms over the past week to aid in the interpretation of other clinical outcomes and explore the cumulative impact of treatment-related side effects. The response options are: "not at all", "a little bit", "somewhat", "quite a bit", and "very much".

    Time frame: From the first dose until the end of 12 months or EOT, whichever comes first (approximately three years)

  64. Module 4: Cancer Antigen 125 (CA125) response evaluated according to the GCIG criteria (for ovarian patients only)

    CA125 response is defined as at least a 50% reduction in CA125 levels from a pre-treatment sample.

    Time frame: From Screening until disease progression or death (approximately three years)

  65. Module 5 : AUC

    To assess the AUC of AZD9574 and Dato-DXd.

    Time frame: AZD9574: Cycle 1 Day X1 (first dose), X2 (last dose), Cycle 2 Day 1, X1 (first dose), Day 15, Cycle 3 Day 1 Dato-DXd: Cycle 1 Day 1, X1 (pre-dose AZD9574), X2, Cycle 2 Day 1, Cycle 4 Day 1, C8D1, every 4 cycles thereafter on Day 1

  66. Module 5 : Cmax

    To assess the Cmax of AZD9574 and Dato-DXd.

    Time frame: AZD9574: Cycle 1 Day X1 (first dose), X2 (last dose), Cycle 2 Day 1, X1 (first dose), Day 15, Cycle 3 Day 1 Dato-DXd: Cycle 1 Day 1, X1 (pre-dose AZD9574), X2, Cycle 2 Day 1, Cycle 4 Day 1, C8D1, every 4 cycles thereafter on Day 1

  67. Module 5 : tmax

    To assess the tmax of AZD9574 and Dato-DXd.

    Time frame: AZD9574: Cycle 1 Day X1 (first dose), X2 (last dose), Cycle 2 Day 1, X1 (first dose), Day 15, Cycle 3 Day 1 Dato-DXd: Cycle 1 Day 1, X1 (pre-dose AZD9574), X2, Cycle 2 Day 1, Cycle 4 Day 1, C8D1, every 4 cycles thereafter on Day 1

  68. Module 5 : Assessment of pH2AX (phospho-histone 2AX) (Ser139) PD biomarker modulations

    To characterise the PD of AZD9574 in tumour tissue, following a single dose and at steady state after multiple dosing, when given orally in combination with Dato-DXd.

    Time frame: Cycle 1 Day X1, Day X2 [last of AZD9574 dosing] (Cycle 1 = 28 days)

  69. Module 5 : Presence of positive ADAs for Dato-DXd

    To investigate the immunogenicity of Dato-DXd.

    Time frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, EoT(End of treatment) ± 7 days, Safety follow up (FU) 28 [+ 7] days after last dose

  70. Module 5: ORR

    ORR is defined as the percentage of participants who have a confirmed response of Complete Response (CR) or Partial Response (PR) prior to any evidence of progression according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1) and PCWG3 for prostate cancer.

    Time frame: From Baseline to every 6 weeks until disease progression (approximately three years)

  71. Module 5: DoR

    The DoR is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression or death in the absence of disease progression according to RECIST v1.1.

    Time frame: First documented response until the date of documented progression or end of study (approximately three years)

  72. Module 5: TTR

    TTR is defined as the time from first dose until the first documentation of a subsequently confirmed objective response according to RECIST v1.1.

    Time frame: From the first dose until the first documentation of a subsequently confirmed objective response (approximately three years)

  73. Module 5: Progression Free Survival (PFS)/radiographic Progression-Free Survival (rPFS)

    PFS and rPFS are defined as the time from start of first treatment until the date of objective disease progression or death regardless of whether the participant withdraws from study therapy or receives another anti-cancer therapy prior to progression according to RECIST v1.1 for solid tumours, RECIST v1.1 and/or PCWG3 for prostate cancer.

    Time frame: From the start of first treatment until the date of objective disease progression or death (approximately three years)

  74. Module 5 : Incidence of AESIs

    To describe the prevalence (or incidence/frequency, etc) of Dato-DXd AESIs in study participants.

    Time frame: From first dose until the safety FU (40 [+ 7] days) after discontinuation

  75. Module 5: Cancer Antigen 125 (CA125) response evaluated according to the GCIG criteria (for ovarian patients only)

    CA125 response is defined as at least a 50% reduction in CA125 levels from a pre-treatment sample.

    Time frame: From Screening until disease progression or death (approximately three years)

  76. Module 5: Proportion of participants achieving a ≥ 50% decrease in PSA from baseline to the post-baseline PSA result (for prostate cancer only)

    PSA50 response is defined as the proportion of participants achieving a ≥ 50% decrease in Prostate Specific Antigen (PSA) from baseline to the lowest post-baseline PSA, confirmed by a consecutive PSA at least 3 weeks later and will be based on PSA evaluable participants.

    Time frame: From screening until disease progression or death (approximately three years)

07

Study locations

25 of 32 sites recruiting
  • Research Site
    La Jolla, California 92093, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Los Angeles, California 90095, United States
    Recruiting
  • Research Site
    San Francisco, California 94143, United States
    Recruiting
  • Research Site
    Chicago, Illinois 60611, United States
    Recruiting
  • Research Site
    Boston, Massachusetts 02215, United States
    Recruiting
  • Research Site
    New York, New York 10040, United States
    Recruiting
  • Research Site
    New York, New York 10065, United States
    Recruiting
  • Research Site
    Portland, Oregon 97239, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78229, United States
    Recruiting
  • Research Site
    Richmond, Virginia 23298, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Darlinghurst, 2010, Australia
    Recruiting
  • Research Site
    Melbourne, 3000, Australia
    Recruiting
  • Research Site
    Randwick, 2031, Australia
    Recruiting
  • Research Site
    Bayern, 80337, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Berlin, 13353, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Heidelberg, 69120, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Mainz, 55131, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Seoul, 03080, South Korea
    Recruiting
  • Research Site
    Seoul, 03722, South Korea
    Recruiting
  • Research Site
    Seoul, 06351, South Korea
    Recruiting
  • Research Site
    A Coruña, 15006, Spain
    Recruiting
  • Research Site
    Barcelona, 8035, Spain
    Recruiting
  • Research Site
    Málaga, 29010, Spain
    Recruiting
  • Research Site
    Pozuelo de Alarcón, 28223, Spain
    Recruiting
  • Research Site
    Sant Cugat del Vallès, 08195, Spain
    Recruiting
  • Research Site
    Seville, 41013, Spain
    Recruiting
  • Research Site
    Lund, 22185, Sweden
    Recruiting
  • Research Site
    Stockholm, 118 83, Sweden
    Recruiting
  • Research Site
    Glasgow, Scotland, G12 0YN, United Kingdom
    Recruiting
  • Research Site
    London, EC1M 6BQ, United Kingdom
    Recruiting
  • Research Site
    Newcastle upon Tyne, NE7 7DN, United Kingdom
    Recruiting
08

References and documents

Publications

  • Staniszewska AD, Pilger D, Gill SJ, Jamal K, Bohin N, Guzzetti S, Gordon J, Hamm G, Mundin G, Illuzzi G, Pike A, McWilliams L, Maglennon G, Rose J, Hawthorne G, Cortes Gonzalez M, Halldin C, Johnstrom P, Schou M, Critchlow SE, Fawell S, Johannes JW, Leo E, Davies BR, Cosulich S, Sarkaria JN, O'Connor MJ, Hamerlik P. Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1. Clin Cancer Res. 2024 Apr 1;30(7):1338-1351. doi: 10.1158/1078-0432.CCR-23-2094. PubMed 37967136 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Feb 2028, 67 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 67 months is above that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2022
First posted
Jun 14, 2022
StartActual
Jun 24, 2022
Primary completionEst.
Feb 7, 2028
CompletionEst.
Feb 7, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Research Site is now Withdrawn
Oct 5, 2026
Secondary outcomes
7 edited, 1 removed, 4 description edited
What changed in the outcomes
  • EditedTime taken to reach maximum plasma concentration (tmax)Time frame: Cycle 0, Cycle 1 Day 1, Cycle 1 Day 16 (Cycle 0 = 7 days; Cycle 1 = 28 days)
  • EditedModule 1: Cancer Antigen 125 (CA125) response evaluated according to the gynecologic cancer intergroup (GCIG) criteria (for ovarian patients only)Time frame: From Screening until disease progression or death (approximately three years)
  • EditedModule 1 (Food effect): TmaxtmaxTime frame: Cycle 0 Day 1,2,3, Cycle 1 Day 1,2,8 to 15 and Cycle 2 Day 1, and Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)
  • EditedModule 1 (ARA effect): TmaxtmaxTime frame: Cycle 0 Day 1,3, Cycle 1 Day 1,2,8 to 15,16, Cycle 2 Day 1, Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)
  • EditedModule 1 (ARA effect) : Cmax ratio (with /without famotidinerabeprazole)Time frame: Cycle 0 Day 1,3, Cycle 1 Day 1,2,8 to 15,16, Cycle 2 Day 1, Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)
  • EditedModule 4 : TmaxtmaxTime frame: AZD9574 (Parts A and B): C1 X1 (first dose), X2 (last dose), C2 D1, X1 (first dose), D15 (part A only), and C3 D1 T DXd: C1 D1, X1 (pre-dose AZD9574), X2, C2 D1, C3 D1, and C4 D1, up to safety follow-up (40-days after last dose)
  • EditedModule 5 : TmaxtmaxTime frame: AZD9574: Cycle 1 Day X1 (first dose), X2 (last dose), Cycle 2 Day 1, X1 (first dose), Day 15, Cycle 3 Day 1 Dato-DXd: Cycle 1 Day 1, X1 (pre-dose AZD9574), X2, Cycle 2 Day 1, Cycle 4 Day 1, C8D1, every 4 cycles thereafter on Day 1
  • RemovedModule 3: Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From first dose to post-treatment follow-up (approximately three years)
  • DescriptionModule 1 (ARA effect): AUC: how it is measured was reworded
  • DescriptionModule 1 (ARA effect): AUC (0-t): how it is measured was reworded
  • DescriptionModule 1 (ARA effect): Cmax: how it is measured was reworded
  • DescriptionModule 3: Occupancy: how it is measured was reworded
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Research Site is now Withdrawn
    Secondary outcomes 7 edited, 1 removed, 4 description edited
    What changed in the outcomes
    • EditedTime taken to reach maximum plasma concentration (tmax)Time frame: Cycle 0, Cycle 1 Day 1, Cycle 1 Day 16 (Cycle 0 = 7 days; Cycle 1 = 28 days)
    • EditedModule 1: Cancer Antigen 125 (CA125) response evaluated according to the gynecologic cancer intergroup (GCIG) criteria (for ovarian patients only)Time frame: From Screening until disease progression or death (approximately three years)
    • EditedModule 1 (Food effect): TmaxtmaxTime frame: Cycle 0 Day 1,2,3, Cycle 1 Day 1,2,8 to 15 and Cycle 2 Day 1, and Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)
    • EditedModule 1 (ARA effect): TmaxtmaxTime frame: Cycle 0 Day 1,3, Cycle 1 Day 1,2,8 to 15,16, Cycle 2 Day 1, Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)
    • EditedModule 1 (ARA effect) : Cmax ratio (with /without famotidinerabeprazole)Time frame: Cycle 0 Day 1,3, Cycle 1 Day 1,2,8 to 15,16, Cycle 2 Day 1, Cycle 3 Day 1 (Cycle 0 = 7 days; Cycle 1 = 28 days)
    • EditedModule 4 : TmaxtmaxTime frame: AZD9574 (Parts A and B): C1 X1 (first dose), X2 (last dose), C2 D1, X1 (first dose), D15 (part A only), and C3 D1 T DXd: C1 D1, X1 (pre-dose AZD9574), X2, C2 D1, C3 D1, and C4 D1, up to safety follow-up (40-days after last dose)
    • EditedModule 5 : TmaxtmaxTime frame: AZD9574: Cycle 1 Day X1 (first dose), X2 (last dose), Cycle 2 Day 1, X1 (first dose), Day 15, Cycle 3 Day 1 Dato-DXd: Cycle 1 Day 1, X1 (pre-dose AZD9574), X2, Cycle 2 Day 1, Cycle 4 Day 1, C8D1, every 4 cycles thereafter on Day 1
    • RemovedModule 3: Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From first dose to post-treatment follow-up (approximately three years)
    • DescriptionModule 1 (ARA effect): AUC: how it is measured was reworded
    • DescriptionModule 1 (ARA effect): AUC (0-t): how it is measured was reworded
    • DescriptionModule 1 (ARA effect): Cmax: how it is measured was reworded
    • DescriptionModule 3: Occupancy: how it is measured was reworded
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05417594
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 14, 2022
Start date
Jun 24, 2022
Primary completion
Feb 7, 2028 (estimated)
Completion
Feb 7, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479
AstraZeneca Breast Cancer Study Locator Service
Contact
az-bcsl@careboxhealth.com
1-877-400-4656

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palacaparib

Start the discussion